摘要
肥厚型心肌病是猫最常见的原发性心脏疾病,典型特征为心脏左心室肥厚。心肌纤维化是猫肥厚型心肌病的标志性病理变化,其可导致心脏功能障碍和节律异常,是心肌病患猫预后不良的重要因素。对于猫肥厚型心肌病与心肌纤维化,目前缺乏针对性治疗,新型治疗方法亟需开发。本综述总结了猫肥厚型心肌病的病理特征以及目前关于猫心肌纤维化发病机制的研究进展,拟通过探索心肌纤维化的发病机制,从而为猫肥厚型心肌病新型治疗药物的开发寻找突破点。
Hypertrophic cardiomyopathy is one of the most common primary heart diseases in cats, which is characterized by left ventricular hypertrophy. Myocardial fibrosis is a cardinal pathological change in cats with hypertrophic cardiomyopathy, which can lead to cardiac dysfunction and rhythm disturbance, and it is an important factor contributing to poor prognosis of cats with cardiomyopathy. There is an urgent need to develop novel drugs targeting cat hypertrophic cardiomyopathy and cardiac fibrosis. This review summarizes the pathological characteristics of cat hypertrophic cardiomyopathy as well as most updated research progress on the pathogenesis of cat myocardial fibrosis, aiming to find a breakthrough point for new therapeutic drug development for cat hypertrophic cardiomyopathy.
作者
陈香凝
刘萌萌
CHEN Xiangning;LIU Mengmeng(College of Animal Science and Technology of Hainan University,Haikou 570228,China)
出处
《畜牧兽医学报》
CAS
CSCD
北大核心
2023年第1期80-87,共8页
ACTA VETERINARIA ET ZOOTECHNICA SINICA
基金
海南大学高层次人才科研启动基金项目(RZ2100003061)
瑞鹏公益基金会高校青年教师(小动物临床)科研基金项目(RH2100005094)。
